Boston Scientific Corporation (FRA:BSX)
Germany
· Delayed Price · Currency is EUR 62.40
+0.80 (1.30%)
Mar 6, 2026, 3:43 PM CET
Boston Scientific Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 20,074 | 16,747 | 14,240 | 12,682 | 11,888 | Upgrade
|
| Revenue Growth (YoY) | 19.87% | 17.61% | 12.29% | 6.68% | 19.92% | Upgrade
|
| Cost of Revenue | 6,267 | 5,290 | 4,391 | 4,003 | 3,760 | Upgrade
|
| Gross Profit | 13,807 | 11,457 | 9,849 | 8,679 | 8,128 | Upgrade
|
| Selling, General & Admin | 6,887 | 5,984 | 5,190 | 4,520 | 4,359 | Upgrade
|
| Research & Development | 2,052 | 1,615 | 1,414 | 1,323 | 1,204 | Upgrade
|
| Amortization of Goodwill & Intangibles | 897 | 856 | 828 | 803 | 741 | Upgrade
|
| Operating Expenses | 9,836 | 8,455 | 7,432 | 6,646 | 6,304 | Upgrade
|
| Operating Income | 3,971 | 3,002 | 2,417 | 2,033 | 1,824 | Upgrade
|
| Interest Expense | -349 | -305 | -265 | -470 | -341 | Upgrade
|
| Interest & Investment Income | 29 | 107 | 22 | 10 | 4 | Upgrade
|
| Currency Exchange Gain (Loss) | -12 | -16 | -41 | -31 | -27 | Upgrade
|
| Other Non Operating Income (Expenses) | -34 | -31 | -15 | -14 | -7 | Upgrade
|
| EBT Excluding Unusual Items | 3,605 | 2,757 | 2,118 | 1,528 | 1,453 | Upgrade
|
| Merger & Restructuring Charges | -101 | -16 | -69 | -24 | -40 | Upgrade
|
| Gain (Loss) on Sale of Investments | 139 | -79 | -59 | -1 | 250 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -22 | 78 | Upgrade
|
| Asset Writedown | -46 | -386 | -58 | -132 | -370 | Upgrade
|
| Legal Settlements | -194 | - | 111 | -173 | -430 | Upgrade
|
| Other Unusual Items | -18 | 5 | -58 | -35 | 136 | Upgrade
|
| Pretax Income | 3,385 | 2,281 | 1,985 | 1,141 | 1,077 | Upgrade
|
| Income Tax Expense | 493 | 436 | 393 | 443 | 36 | Upgrade
|
| Earnings From Continuing Operations | 2,892 | 1,845 | 1,592 | 698 | 1,041 | Upgrade
|
| Minority Interest in Earnings | 6 | 8 | 1 | - | - | Upgrade
|
| Net Income | 2,898 | 1,853 | 1,593 | 698 | 1,041 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 23 | 56 | 56 | Upgrade
|
| Net Income to Common | 2,898 | 1,853 | 1,570 | 642 | 985 | Upgrade
|
| Net Income Growth | 56.39% | 16.32% | 128.22% | -32.95% | - | Upgrade
|
| Shares Outstanding (Basic) | 1,480 | 1,472 | 1,453 | 1,431 | 1,422 | Upgrade
|
| Shares Outstanding (Diluted) | 1,495 | 1,486 | 1,464 | 1,440 | 1,434 | Upgrade
|
| Shares Change (YoY) | 0.58% | 1.53% | 1.65% | 0.41% | 1.21% | Upgrade
|
| EPS (Basic) | 1.96 | 1.26 | 1.08 | 0.45 | 0.69 | Upgrade
|
| EPS (Diluted) | 1.94 | 1.25 | 1.07 | 0.45 | 0.69 | Upgrade
|
| EPS Growth | 55.20% | 16.82% | 138.42% | -34.96% | - | Upgrade
|
| Free Cash Flow | 3,658 | 2,645 | 1,792 | 938 | 1,316 | Upgrade
|
| Free Cash Flow Per Share | 2.45 | 1.78 | 1.22 | 0.65 | 0.92 | Upgrade
|
| Gross Margin | 68.78% | 68.41% | 69.16% | 68.44% | 68.37% | Upgrade
|
| Operating Margin | 19.78% | 17.93% | 16.97% | 16.03% | 15.34% | Upgrade
|
| Profit Margin | 14.44% | 11.06% | 11.03% | 5.06% | 8.29% | Upgrade
|
| Free Cash Flow Margin | 18.22% | 15.79% | 12.58% | 7.40% | 11.07% | Upgrade
|
| EBITDA | 5,339 | 4,271 | 3,613 | 3,169 | 2,917 | Upgrade
|
| EBITDA Margin | 26.60% | 25.50% | 25.37% | 24.99% | 24.54% | Upgrade
|
| D&A For EBITDA | 1,368 | 1,269 | 1,196 | 1,136 | 1,093 | Upgrade
|
| EBIT | 3,971 | 3,002 | 2,417 | 2,033 | 1,824 | Upgrade
|
| EBIT Margin | 19.78% | 17.93% | 16.97% | 16.03% | 15.34% | Upgrade
|
| Effective Tax Rate | 14.56% | 19.11% | 19.80% | 38.82% | 3.34% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.